Moderna and Merck Report Melanoma Vaccine Success in Large Trial
Moderna and Merck report their personalized mRNA melanoma vaccine succeeded in a large clinical trial, a milestone for mRNA cancer immunotherapy in skin cancer.
Topic
Moderna
Topic
Moderna
Moderna-Merck mRNA Vaccine Succeeds in Late-Stage Melanoma Trial
Moderna and Merck said their mRNA cancer vaccine succeeded in a late-stage melanoma trial, per statnews.com, but effect size, end…
Moderna Brings More Melanoma Trial Data to ESMO Congress
Moderna will present additional melanoma trial data at the ESMO Congress, and retail analysts say the breakout is getting hard to…
Moderna Shares Surge 29.1% on Melanoma Vaccine Data
Moderna stock jumped 29.1% after reported melanoma vaccine success and Middle East expansion talks, boosting market confidence in…
Moderna Shares Jump on Melanoma Vaccine Trial Readout
Moderna shares surged after a melanoma vaccine trial delivered what observers called a landmark moment, moving markets and signal…
Moderna Stock Jumps 9% on Phase 3 Melanoma Slot at Symposium
Moderna stock surged 9% after its Phase 3 melanoma data earned a Presidential Symposium slot, lifting Merck and BioNTech; full en…
Moderna and Merck Cancer Vaccine Breakthrough Reported
A Moderna and Merck breakthrough could trigger a wave of cancer vaccine development, CNN reports — an advance dermatology is watc…
Moderna and Merck Revive mRNA Prospects With Melanoma Success
Moderna and Merck report a melanoma success that revives hopes for mRNA technology, pointing toward personalized cancer vaccines…